NSC

National Stem Cell (NSC) was a biotechnology company focused on the development of stem cell-based therapies and the management of stem cell banks. The company aimed to advance regenerative medicine by utilizing both adult and embryonic stem cells for the treatment of various conditions, including diabetes and heart disease. NSC operated the National Stem Cell Bank and engaged in research to develop proprietary cell lines and therapeutic applications. Despite its early promise in the burgeoning field of regenerative medicine during the mid-2000s, the company faced significant financial and regulatory challenges. It eventually ceased active operations and its stock was delisted.